Toxoplasma gondii Pneumonia in an Immunocompetent Individual

Shen, Changxing; Zhang, Guoliang; Song, Xiaolian; Xie, Shuanshuan; Wang, Changhui

doi:10.1097/maj.0000000000000496

Cited by 4 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data are presented as mean ± SD. (D) The size of the area (µm 2 ) of parasitophorous vacuole (PV) among the indicated treatments. One hundred PVs in each condition were quantified using ImageJ software.…”

Section: Resultsmentioning

confidence: 99%

“…Upon reaching confluency, T. gondii tachyzoites were placed onto Vero cells at a density of 10 5 /cm 2 and then incubated with 5% CO 2 at 37 °C. Following a 3-h incubation for parasite invasion, we performed a single wash of the plate using phosphate-buffered saline (PBS) (+) to eliminate any uninvaded tachyzoites.…”

Section: Methodsmentioning

confidence: 99%

“…To assess the cytotoxicity of OA in host cells (Vero), we examined the SRB (Tokyo Chemical Industry) cytotoxicity assay 22,23 . Briefly, Vero cells were seeded at a density of 10 5 /cm 2 in 24-well plates (Thermo Fisher Scientific, MA) and maintained in DMEM supplemented with 2% FBS. After two days of cell seeding, we confirmed the cell condition, i.e., confluence, before adding various concentrations (5 to 100 µM) of OA, PYR as an effective compound for anti-toxoplasmosis, or DMSO as a negative control to each well.…”

Section: Methodsmentioning

confidence: 99%

“…In humans, toxoplasmosis caused by this parasite typically remains asymptomatic in patients with a typical immune system. However, in cases involving immunocompromised patients, such as those with human immunodeficiency virus infection, organ transplantation, or pregnancy, T. gondii becomes activated within the host's organs, leading to severe diseases like toxoplasmic encephalitis, ocular toxoplasmosis, and Toxoplasma pneumonia [2][3][4] . In general, pyrimethamine (PYR) and sulfadiazine are clinically used to treat acute toxoplasmosis.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Suppressive effects of oroxylin A on intracellular proliferation ofToxoplasma gondiivia host cell ERK phosphorylation inhibition

Zhang,

Norose,

Shinjyo

et al. 2024

Preprint

View full text Add to dashboard Cite

Toxoplasma gondii poses a significant threat to immunocompromised patients, resulting in high mortality rates. Considering the side effects of anti-Toxoplasma drugs, we focused on a potential candidate, oroxylin A (OA), a common component extracted from Astragalus membranaceus and Scutellaria baicalensis which suppressed the growth of T. gondii in vitro and in vivo. Our result demonstrated that OA suppressed T. gondii intracellular proliferation and downregulated phosphorylation of ERK1/2 of T. gondii-infected host cells very similar to the MEK1 specific inhibitor PD98059. Our in silico analysis showed that OA interacts sufficiently with the mammalian MEK1 region where established MEK1 inhibitors like PD98059 and trametinib bind. Moreover, OA improved the survival rate in T. gondii-infected mice. This study proposes that host MEK1 is a novel potential target for anti-Toxoplasma drugs with a new mechanism of action.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Suppressive effects of oroxylin A on intracellular proliferation ofToxoplasma gondiivia host cell ERK phosphorylation inhibition

Zhang,

Norose,

Shinjyo

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…T. gondii infection activates the mononuclear phagocytic system and plays a role in phagocytosis. The immune system of an immunocompetent host then generates an immune response, the infection is controlled [ 8 ]. The hypotheses for pulmonary involvement by T. gondii in immunocompetent patients are related to the means of contamination.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary and Renal Toxoplasmosis in an Immunocompetent Adult Patient

2023

View full text Add to dashboard Cite

Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii (T. gondii), which is one of the most widespread zoonotic pathogens known today. It is a global health hazard as they infect 30-50% of the world's human population. Acute toxoplasmosis is usually asymptomatic and self-limited in immunocompetent people, recovering without treatment and do not require specific therapy. Therefore, rare complications are associated with infection in the individuals with normal immune systems. However, we present a rare case of an immunocompetent man with acute T. gondii infection confirmed by serology, subsequently presented with two life-threatening organ dysfunctions: severe renal and pulmonary involvement, requiring hospitalization and anti-parasitic treatment.

show abstract

Toxoplasma gondii (Toxoplasmosis)

Contopoulos‐Ioannidis¹,

Montoya²

2023

Principles and Practice of Pediatric Infectious Diseases

View full text Add to dashboard Cite

Toxoplasma gondii Pneumonia in an Immunocompetent Individual

Cited by 4 publications

References 6 publications

Suppressive effects of oroxylin A on intracellular proliferation ofToxoplasma gondiivia host cell ERK phosphorylation inhibition

Suppressive effects of oroxylin A on intracellular proliferation ofToxoplasma gondiivia host cell ERK phosphorylation inhibition

Pulmonary and Renal Toxoplasmosis in an Immunocompetent Adult Patient

Toxoplasma gondii (Toxoplasmosis)

Contact Info

Product

Resources

About